Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · September 11, 2023

High-Dose Intravenous Immunoglobulin Co-Treatment Prolongs Time to Treatment Escalation in Patients With Autoimmune Bullous Diseases

Journal of the European Academy of Dermatology and Venereology: JEADV


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the European Academy of Dermatology and Venereology: JEADV
High-dose intravenous immunoglobulin co-treatment prolongs time-to-treatment escalation in autoimmune bullous diseases: A monocentric retrospective cohort study
J Eur Acad Dermatol Venereol 2023 Aug 18;[EPub Ahead of Print], M Bertlich, I Bertlich, N Plümacher, E Hadaschik, A Enk, JHO Hoffmann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading